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Abstract
Our laboratory is interested to develop oncolytic adenoviral vectors that can be administered
systemically for the treatment of breast cancer. To restrict viral replication in breast tumor cells,
we have constructed mhTERTAd.sTβRFc, a 01/07 based adenoviral vector expressing the soluble
form of TGFβ receptor II fused with human Fc IgG1 (sTGFβRIIFc) gene, in which viral
replication is under the control of modified human telomerase reverse transcriptase (mhTERT)
promoter. In addition, mhTERTAd.sTβRFc-mediated sTGFβRIIFc production would target
growth factor-β (TGFβ) pathway known to contribute to the tumor progression breast cancer
metastasis. We chose to use mhTERT promoter because it was found to be relatively more active
(approximately 20-times) in breast cancer cells compared to normal human cells. We showed that
infection of MDA-MB-231 and MCF-7 breast cancer cells for 48 hrs with mhTERTAd.sTβRFc
produced high levels of sTGFβRIIFc (greater than 1 μg/ml) in the medium. Breast cancer cells
produced nearly 6,000-fold increase in the viral titers during 48 hrs infection period. However,
mhTERTAd.sTβRFc replication was attenuated in normal cells. Infection of breast cancer cells
with a replication deficient virus Ad(E1-).sTβRFc also produced high levels of sTGFβRIIFc, but
under these conditions no detectable viral replication was observed. Adenoviral-mediated
production of sTGFβRIIFc was shown to bind with TGFβ-1, and abolished the effects of TGFβ-1
on downstream SMAD-3 phosphorylation. The administration of mhTERTAd.sTβRFc
intravenously into MDA-MB-231 human xenograft bearing mice resulted in significant inhibition
of tumor growth, and production of sTGFβRIIFc in the blood. On the other hand, intravenous
injection of Ad(E1-).sTβRFc did not exhibit significant inhibition of the tumor growth, but
resulted in the sTGFβRIIFc in the blood, suggesting that viral replication along with sTGFβRIIFc
protein production play a critical role in inducing inhibition of tumor growth. These results
warrant future investigation of mhTERTAd.sTβRFc as an anti-tumor agent in vivo.
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Introduction
Nearly 200,000 women are diagnosed with breast cancer resulting in approximately 30,000
deaths each year in the United States.1 Thus, there is a tremendous need to develop novel
approaches to treat breast cancer. In recent years, tumor specific replicating adenoviruses
have been proposed as potential gene therapy vehicles to target cancer.2-5 Our long-term
goals are to develop gene therapy approaches to treat breast cancer, and have chosen to
develop oncolytic adenoviral (dl01/07 based) vectors. The adenoviral mutant 01/07 has two
deletions in the E1A (Rb and p300 binding) and replicates in cancer cells regardless of their
genetic background.6 In addition, we would target growth factor-β (TGFβ) pathway because
high levels of TGFβ protein and activated SMAD signaling are known to contribute to
tumor progression, and are associated with metastasis in breast cancer patients.7-14
Recently, we have developed an oncolytic adenoviral vector (dl01/07 based) expressing the
soluble form of TGFβ receptor II fused with human Fc IgG1 (sTGFβRIIFc) (Ad.sTβRFc).6
To further restrict dl01/07 viral replication in breast tumor cells, we report here the
construction of mhTERTAd.sTβRFc, a modified 01/07 based adenoviral vector expressing
sTGFβRIIFc gene in which viral replication is under the control of a modified human
telomerase reverse transcriptase (mhTERT) promoter. To examine the potential application
of mhTERTAd.sTβRFc as an anti-tumor agent, we have conducted in vitro and in vivo
experiments using mhTERTAd.sTβRFc in human breast cancer models. Our data presented
here shows that it is feasible to create mhTERTAd.sTβRFc; achieve mhTERTAd.sTβRFc
replication in breast cancer cells, and simultaneously produce sTGFβRIIFc that can inhibit
TGFβ signaling in human breast cancer cells, and that intravenous administration of
mhTERTAd.sTβRFc can inhibit tumor growth. These results warrant future investigation of
mhTERTAd.sTβRFc as an anti-tumor agent in vivo.
Materials and Methods
Cell culture
HEK-293, MCF-7, IMR-90 cells were obtained from ATCC, MDA-MB-231 cells were
obtained as described earlier.13 Cells were cultured in Dulbecco's Modified Eagle's Medium
(DMEM) (Mediatech, Inc., Manassas, VA) containing 10% fetal bovine serum (FBS)
(Mediatech, Inc., Manassas, VA) and 1% penicillin/streptomycin (Invitrogen).
Construction of Recombinant viral vectors
To create mhTERTAd.sTβRFc, A 0.7 kb fragment of mhTERT15 was cloned in p01/07
shuttle plasmid to produce p01/07mhTERT shuttle vector in which E1A 01/07 gene was
controlled by mhTERT promoter. The shuttle vector (PmeI digested) was recombined with
PacI cut p01/07/sTβRFc in E. coli BJ5183 to produce pmhTERT01/07/sTβRFc viral
backbone plasmid. The resulting plasmid was digested with PacI and transfected into
HEK-293 cells to generate mhTERTAd.sTβRFc adenovirus. Ad(E1-).sTβRFc, an E1 minus,
replication-deficient adenovirus expressing sTGFβRIIFc was created by homologous
recombination procedures using established methods (Clontech, Palo Alto, CA). A
replication-deficient adenorvirus devoid of any transgene Ad(E1-).Null has been described
previously. 16 The adenoviruses were grown in HEK-293 cells and purified by double
CsCl2 density gradient.
Western blot analysis of sTGFβRIIFc produced by mhTERTAd.sTβRFc or Ad(E1-).sTβRFc -
infected cells
Breast tumor cells (0.2×106 cells per well in 6-well plates) were plated in DMEM containing
10% FBS and incubated at 37°C overnight. The next morning, cells were infected with 100
plaque forming units (pfu)/cell of mhTERTAd.sTβRFc, Ad(E1-).sTβRFc or Ad(E1-).Null
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for 24 hours. Cells were washed and incubated with DMEM without FBS for 24 hours.
Media and cells were subjected to Western blot analysis as previously described16,17. Blots
were probed with antibody reactive against TGFβRII (H-567; Santa Cruz Biotechnology,
Santa Cruz, CA) or actin protein (I-19; Santa Cruz Biotechnology, Santa Cruz, CA).
ELISA assays of sTGFβRIIFc produced by mhTERTAd.sTβRFc and Ad(E1-).sTβRFc -
infected cells
Supernatants obtained from the mhTERTAd.sTβRFc, Ad(E1-).sTβRFc or Ad(E1-).Null
infected cells were analyzed for sTGFβRIIFc expression by ELISA using published method.
18 In brief, 96-well plates (Nunc, Roskilde, Denmark) were coated with the anti-human
IgG-Fc specific capture antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
incubated with various dilutions of the samples, followed by detection with biotinylated
anti-human TGFβ RII antibody (R&D systems, Minneapolis, MN). The detection was
carried out with streptavidin conjugate peroxidase using TMB/HRP substrate (BioFX
Laboratories, Owing Mills, MD). After stopping the reaction with 1N HCl, the absorbance
was measured at 450 nm using a SPECTRA max Plus ELISA plate reader (Molecular
Devices, Sunnyvale, CA). Standard curves of sTGFβRIIFc were used to calculate the
sTGFβRIIFc concentrations in the test samples.
Affinity purification of sTGFβRIIFc and binding of sTGFβRIIFc and TGFβ1
MDA-MB-231 cells were infected with Ad.sTβRFc (100 pfu/cell) for 24 hrs. Medium was
changed into serum free medium for additional 24 hrs. The medium was collected and
applied to Protein A Sepharose column. The sTGFβRIIFc was eluted with 100mM glycine
buffer (pH 4). The eluted protein solution was neutralized by Tris buffer, pH 9.0, dialyzed
against 20mM Tris (pH 7.5) and stored at -70°.
For binding of TGFβ-1 with sTGFβRIIFc, TGFβ-1 (Sigma, St. Louis, MO) protein was
mixed with sTGFβRIIFc, and incubated for 1 hr at 4°C. The complexes were mixed with
Protein A Sepharose beads (Vector Laboratories, Burlingame, CA), and incubated at 4°C for
1 hr. Samples were centrifuged at 13,000g, 4°C, 1 min, and the beads washed 4 times with
wash buffer (50mM NaCl, 10 mM Tris-Cl, 5 mM EDTA, 1% Triton X-100 pH 7.4).
Samples were resuspended in elution buffer (100mM glycine buffer pH 4) and centrifuged at
4°C, 5 min. Proteins were neutralized with TrisCl (pH 9.0), subjected to Western blot
analysis and probed with anti-TGFβ-1 (R & D systems, Minneapolis, MN).
SMAD phosphorylation studies
Cells were plated in 6-well plate (4×105 cells/well), and starved for 24 hours in serum free
media. The cells were then washed with serum free media before treatment with the
indicated concentrations of recombinant TGFβ-1 (Sigma, St. Louis, MO) for one hour. Cells
were lysed in 250 μL of lysis buffer containing 0.1mM phenylmethylsulfonyl fluoride,
sonicated and stored at -80°C until further use. Equal amounts of cell lysates were separated
by SDS-PAGE on 10% acrylamide gels and transferred to nitrocellulose membranes. The
membranes were blocked in Blotto A for one hour at room temperature and treated with
phospho-SMAD3 or SMAD2/3 primary antibodies (Cell Signaling, Danvers, MA) followed
by horseradish peroxidase-conjugated bovine anti-rabbit IgG secondary antibody (Santa
Cruz Biotechnology, Santa Cruz, CA). The blots were visualized by enhanced
chemiluminescence substrate (Amersham Biosciences, Piscataway, NJ).
Viral titer assay
Cells were plated in six-well plates at about 70% confluence and the viral titers were
examined using the published method6,19 with some modifications. Cells were infected
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with mhTERTAd.sTβRFc, Ad(E1-).sTβRFc or Ad(E1-).Null for 3 hrs at a multiplicity of
infection (MOI) of 100. Cells were washed with DMEM and incubated in 1 ml DMEM for
additional one hr at 37°C. At the end of the incubation, cells were washed and either
collected in 0.5 ml growth media and frozen at -70°C, or were maintained in 2 ml of growth
media for additional 48 hrs. Media and cells were collected, and cells were subjected to
three cycles of freezing and thawing to release the viruses. The total viruses from media and
cells were serially diluted and added to monolayers of HEK-293 cells respectively. After 3
hrs of incubation at 37°C, the infected HEK-293 cells were overlaid with 3 ml of 1.25%
SeaPlaque agarose (Cambrex, East Rutherford, NJ) in growth media. Plaques were counted
following 7-8 days incubation using published methods.20 To calculate the viral burst size,
viral titers at 48 hrs were divided by the viral titers present in 3 hrs samples of various cell
lines.
β-gal assays
Cells were plated in 6-well plate (105 cell per well), and next day were infected with
adenoviral vectors expressing β-galactosidase (β-gal) for 24 hrs and examined for β-gal as
described earlier.16,21 At the end of the incubation, cells were washed three times with PBS
(pH 7.5) and lysed in 200 μl of 0.1 M Tris (pH 7.5) containing 0.1% Triton x-100. An
aliquot (30 μl) was assayed for β-gal activity. Samples were treated with 100 μl 20 mM Tris
(pH 7.5) containing 1 mM MgCl2, 450 mM β mercaptoethanol, and 150 mM O-
nitrophenyl-3-galactopyranoside. Incubations were performed at 37°C for 20 min, and the
reaction was stopped by the addition of 100 μl/well of 1 M Na2CO3. The absorbance was
determined at 420 nm. An A420 of 1.0 was defined as 1.0 unit of enzyme activity.
Evaluating anti-tumor responses in vivo in breast tumor model
MDA-MB-231 cells were injected subcutaneously in 4 weeks old nude mice (Nu/Nu) (5 ×
106 cells/mouse). After about a week, when the tumor sizes reached about 50 mm3 (day 0),
mhTERTAd.sTβRFc or Ad(E1-).sTβRFc or Ad(E1-).Null vectors were injected into the tail
vein (2×108 pfus in 0.1 ml buffer per injection, two injections total on days 0 and 3). Tumor
sizes were measured once a week by a digital caliper. Tumor volumes were calculated using
the formula (a × b2) × 0.523, whereby a is the larger dimension, and b is the smaller
dimension. At the end of the experiment blood was collected by intracardiac puncture. All
animal protocols were approved by IACUC of the NorthShore Research Institute.
Statistical analysis
For in vitro studies, experimental groups were compared by t-tests, two tailed analysis, using
GraphPad Prism software version 5 (GraphPad Software, San Diego, CA). For in vivo
studies, comparisons among different treatment groups were done by the two-way ANOVA
method and the Bonferroni post hoc test using the commercial software GraphPad Prism 5
(GraphPad Software, San Diego, CA). P < 0.05 was considered to be significant difference.
All the data points were presented as mean ± SE (standard error).
Results
mhTERT promoter is much more active in breast tumor cells compared to the normal cells
Before creating mhTERT promoter-driven oncolytic viruses, we wanted to examine whether
mhTERT promoter would have enhanced transcriptional activity in breast tumor cells as
compared to the normal cells. Breast tumor (MDA-MB-231, MCF-7) and normal human
cells (IMR-90) were exposed to E1 deleted Ad(E1-).mhTERTLacZ in which mhTERT
promoter drives the expression of a marker β-gal gene15, or E1 deleted Ad(E1-).CMVLacZ
in which CMV promoter drives β-gal expression15. β-gal activity was quantified, and the
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results are shown in Fig 1. All three cell lines produced high levels of β-gal activity when
infected with Ad(E1-).CMVLacZ. β-gal activity was relatively lower in each cell line
infected with Ad(E1-).mhTERTLacZ. However, the β-gal activity was markedly reduced in
IMR-90 cells (Fig. 1A). To evaluate the relative activities of the CMV and mhTERT
promoters, the ratios of β-gal activities obtained from Ad(E1-)CMVLacZ vs.
Ad(E1-)mhTERTLacZ viruses were calculated in each cell line and are shown in Fig.1 B.
While, CMV promoter was 6.1 and 7.7 fold more active than mhTERT promoter in MDA-
MB-231 and MCF-7 breast tumor cells respectively, it was 115- fold more active than
mhTERT promoter in IMR-90 normal cells (Fig.1 B). These results indicate that mhTERT
promoter incorporated in adenovirus backbone is about 20-times more active in breast
cancer cells compared to normal human cells (p values < 0.05), favoring the use of mhTERT
promoter in the oncolytic adenoviruses.
Construction of mhTERT driven 01/07 based oncolytic adenovirus
To examine the use of mhTERT promoter in the context of 01/07 oncolytic viral replication,
an oncolytic adenovirus mhTERTAd.sTβRFc was constructed using homologous
recombination method (Fig. 2). In this viral construct, mhTERT promoter regulates E1A
expression. The key elements in this viral genome are mhTERT driving a mutant E1A
region (01/07) and the expression cassette containing sTGFβRIIFc (part of E3 containing
adenovirus death protein is left intact) (Fig. 2). Rest of the genomic structure of
mhTERTAd.sTβRFc is identical to wild type Ad5.
Infection of human breast cancer cells with mhTERTAd.sTβRFc and Ad(E1-).sTβRFc
produce sTGFβRIIFc that is secreted into the medium
To investigate if the infection of breast cancer cells with mhTERTAd.sTβRFc and
Ad(E1-).sTβRFc can produce sTGFβRIIFc protein, breast cancer cells were infected with
mhTERTAd.sTβRFc or Ad(E1-).sTβRFc and the protein expression was examined using
Western blot analysis. As shown in Fig. 3A, infection of MDA-MB-231 and MCF-7 cells
with mhTERTAd.sTβRFc showed 60-80 Kd protein band of sTGFβRIIFc. Similarly, the
extracellular media of mhTERTAd.sTβRFc also showed the presence of sTGFβRIIFc.
Infection of cells with Ad(E1-).sTβRFc also produced sTGFβRIIFc as shown by the
presence of protein band in the Ad(E1-).sTβRFc-infected cells. However, sTGFβRIIFc
protein was not detectable in the cell lysates or the media of the tumor cells infected with a
Ad(E1-).Null (Fig. 3A). The amounts of sTGFβRIIFc in the supernatants of
mhTERTAd.sTβRFc and Ad(E1-).sTβRFc -infected breast cancer cells were quantified by
ELISA method. These amounts were found to be 2.22 μg/ml and 1.13 μg/ml in MDA-
MB-231 and MCF-7 cells respectively in mhTERTAd.sTβRFc infected cells (Fig. 3B).
Similar amounts of sTGFβRIIFc were found in Ad(E1-).sTβRFc-infected MDA-MB-231
and MCF-7 cells (Fig. 3B). These results indicate that infection of breast tumor cells with
mhTERTAd.sTβRFc or Ad(E1-).sTβRFc can produce sTGFβRIIFc that is subsequently
released into the media. Thus, incorporation of mhTERT promoter driving E1A expression,
did not adversely affect the expression of sTGFβRIIFc.
mhTERTAd.sTβRFc-dependent production of sTGFβRIIFc in breast cancer cells can bind
with TGFβ-1 and inhibit TGFβ-dependent SMAD-3 phosphorylation
To examine the binding capacity of sTGFβRIIFc with TGFβ, sTGFβRIIFc was incubated
with TGFβ-1 for 30 minutes at room temperature and mixed with Protein A sepharose
beads. The beads were centrifuged, the sTGFβRIIFc-TGFβ complexes were eluted by
denaturing buffer and subjected to Western blot analysis. The blots were probed with anti-
TGFβ-1 antibody. The detection of TGFβ-1 in the precipitate from sTGFβRIIFc-TGFβ
complexes indicating that secreted sTGFβRIIFc can form complexes with TGFβ-1 (Fig 4A).
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In order to examine if the mhTERTAd.sTβRFc-mediated sTGFβRIIFc expression can lead
to the inhibition of TGFβ-dependent signal transduction, the effect of sTGFβRIIFc on the
inhibition of TGFβ-dependent SMAD-3 phosphorylation was examined. MDA-MB-231
cells were exposed to TGFβ-1 in the absence or presence of the extracellular media
containing the sTGFβRIIFc or the purified sTGFβRIIFc protein. As shown in Fig. 4B,
TGFβ-1 induced SMAD-3 phosphorylation in MDA-MB-231 cells, and this
phosphorylation was inhibited by the crude media containing sTGFβRIIFc, as well as by the
purified sTGFβRIIFc (Fig. 4B). These results suggest that sTGFβRIIFc derived form
mhTERTAd.sTβRFc-infected breast tumor cells is functionally active.
mhTERTAd.sTβRFc can replicate in human breast cancer cells, but has reduced
replication potential in normal cells
Next, we examined the replication potential of mhTERTAd.sTβRFc in breast cancer cells.
Breast cancer cells were exposed to mhTERTAd.sTβRFc and the viral titers measured at 3
hrs (basal level) and at 48 hrs. As shown in Fig. 5A, in MDA-MB-231 cells, at 3 hrs, the
mhTERTAd.sTβRFc viral titer was 5.17×102. This titer was increased to 3.2×106 in 48 hrs,
indicating a 6,189 fold increase in viral titer. The increase in viral titers from 3 hrs to 48 hrs
is described here as the “viral burst size” (Fig. 5A, B). Similar increase (6,285-fold) in burst
size was observed in MCF-7 cells (Fig. 5B). On the other hand, infection of MDA-MB-231
or MCF-7 cells with Ad(E1-).sTβRFc or Ad(E1-).Null resulted in less than 2-fold increase in
viral burst size (data not shown), suggesting that Ad(E1-).sTβRFc is replication-deficient in
the breast cancer cells. Using these viral replication assays, burst size of
mhTERTAd.sTβRFc was also compared in normal human cells. The burst size of
mhTERTAd.sTβRFc was about 16-fold lower in IMR-90 cells compared to the breast tumor
cells (Fig. 5A, B). The burst size of mhTERTAd.sTβRFc was about 16-fold higher in breast
tumor cells compared to IMR-90 cells (p <0.001) (Fig. 5 B). These results indicate
mhTERTAd.sTβRFc replication is attenuated in normal cells while maintaining the
replication potential in the breast tumor cells.
Intravenous delivery of mhTERTAd.sTβRFc into MDA-MB-231 tumors bearing mice causes
inhibition of tumor growth, and produces high levels of sTGFβRIIFc in the blood
Next, we conducted experiments to evaluate in vivo efficacy of mhTERTAd.sTβRFc in a
human breast xenograft model. MDA-MB-231 human xenograft tumors were established in
nude mice. mhTERTAd.sTβRFc, Ad(E1-).sTβRFc or Ad(E1-).Null or buffer were injected
into the tail vein. Tumor sizes were measured once a week and are shown in Fig 6A. In the
control group of animals, tumors grew rapidly. However, in the group of animals that
received mhTERTAd.sTβRFc, there was a significant inhibition of tumor growth over time
(p value <0.01 compared to buffer control). Intravenous injection of Ad(E1-).sTβRFc
showed some inhibition of tumor growth, however, the inhibition of the tumor growth in
Ad(E1-).sTβRFc treated group of animals was not statistically significant compared to
buffer treated group (p values >0.05). Ad(E1-).Null had no significant inhibition on tumor
growth (p value >0.05) compared to buffer group suggesting that the anti-tumor responses of
mhTERTAd.sTβRFc require viral replication in addition to sTGβRIIFc production.
To examine if the intravenous delivery of mhTERTAd.sTβRFc in the experiments described
above produces high levels of sTGFβRIIFc, blood samples were collected at the end of the
experiment (day 35). Aliquots of blood samples were analyzed for the presence of
sTGFβRIIFc using ELISA method described in Materials and Methods. In
mhTERTAd.sTβRFc treated group, the levels of sTGFβRIIFc present in the blood were
17.64 ± 3.99 mg/ml (Fig 6B). Similarly, E1-Ad.sTβRFc treated group also produced high
levels (9.45 ± 2.59 mg/ml) of sTGFβRIIFc (Fig. 6B). As expected animals that received
buffer or Ad(E1-).Null had very low levels sTGFβRIIFc (less than 5 pg/ml) in the blood.
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These results show that the intravenous delivery of mhTERTAd.sTβRFc as well as
sTGFβRIIFc into the mice results in the release of sTGFβRIIFc protein in the blood.
However, since mhTERTAd.sTβRFc is more effective as an anti-tumor agent, suggests that
perhaps viral replication as well as sTGFβRIIFc production play an important role in
producing inhibition of tumor growth following intravenous delivery of the viral vectors.
Discussion
There is a tremendous need to create novel approaches to treat breast cancer. In recent years
tumor specific replicating adenoviruses have been proposed as potential gene therapy
vehicles to target cancer 2-5. Given that breast caner often metastasizes to other organs,
there is a need to develop replicating adenoviruses that could be administered systemically
for the treatment of breast cancer. 5 Results presented here indicated that modified hTERT
promoter is relatively more specific than CMV promoter for targeting breast cancer,
strengthening the idea to use oncolytic adenoviruses in which E1A expression would be
controlled by mhTERT promoter. mhTERTAd.sTβRFc virus was created by the
homologous recombination procedures previously established in our laboratory. In vitro
results suggested that in cancer cells supported the mhTERTAd.sTβRFc replication and the
viral replication was attenuated in normal cells, indicating a potential advantage to use
mhTERTAd.sTβRFc for in vivo research. Another important feature of
mhTERTAd.sTβRFc is that it has retained the capacity to express the sTGFβRIIFc protein.
These results therefore, suggest that mhTERT-driven E1A expression does not compromise
with the ability of mhTERTAd.sTβRFc to replicate or to produce the sTGFβRIIFc in the
breast tumor cells.
Another important finding being reported here is that the adenoviral-mediated sTGFβRIIFc
produced is functionally active. In vitro assays showed that sTGFβRIIFc can bind with
TGFβ-1, and inhibit TGFβ-dependent SMAD-3 phosphorylation. The inhibition of SMAD
phosphorylation production are of particular significance as higher levels of SMAD
phosphorylation is linked with the progression of breast cancer metastasis.10,14,22,23 We
also report that systemic administration of mhTERTAd.sTβRFc via tail vein causes
significant inhibition of tumor growth of human xenograft model in nude mice. The
mhTERTAd.sTβRFc treated animals also produce high levels of sTGFβRIIFc in the blood,
although, in this limited set of animals, it is difficult to correlate mhTERTAd.sTβRFc-
mediated sTGFβRIIFc expression and in vivo anti-tumor responses of the local tumors. An
important point to note that a replication-defective virus when injected systemically, though
also produced high levels of sTGFβRIIFc in the blood, was less effective than
mhTERTAd.sTβRFc in inhibiting the tumor growth. These results clearly suggest that while
the viral replication is critical for anti-tumor responses at least in this particular tumor model
and the route of viral injection. Since TGFβ appears to play a major role in breast cancer
associated bone metastasis7-14. Our future studies will be designed to examine the effect of
mhTERTAd.sTβRFc-mediated sTGFβRIIFc protein production in causing the inhibition of
bone metastasis and osteolytic bone destruction.
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Fig. 1.
A. CMV and mhTERT promoter driven β-gal activities in breast tumor and normal cells.
Various cells were plated in 6-wells (2×104 cells/well) and infected with
Ad(E1-).CMVLacZ or Ad(E1-).mhTERTLacZ viruses (100 pfus/cell). Forty eight hrs later,
cells were lysed and β-gal activities measured by staining with o-nitrophenyl-β-D-
galactopyranoside (ONPG) using published methods16,21. Shown are the averages of
triplicate samples (±SE). B. Ratios of β-gal obtained from CMV promoter-directed and
mhTERT promoter-directed β-gal activities. Ratios shown were obtained from Panel A.
These ratios were significantly lower in IMR-90 cells compared to MDA-MB-231 or
MCF-7 cells (p values < 0.05).
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Fig. 2.
A. Construction of mhTERTAd.sTβRFc. A 0.7 kb fragment of mhTERT was cloned in
p01/07 shuttle plasmid to produce p01/07mhTERT shuttle vector in which E1A 01/07 gene
was controlled by mhTERT promoter. The shuttle vector (PmeI cut) was recombined with
PacI cut p01/07/sTβRFc in E. coli BJ5183 to produce pmhTERT01/07/sTβRFc viral
backbone plasmid. The resulting plasmid was cut with PacI and transfected into HEK-293
cells to generate mhTERTAd.sTβRFc adenovirus. The Adenovirus was grown in HEK293
cells and purified by double CsCl2 density gradient. B. Schematic structure of recombinant
mhTERTAd.sTβRFc. The key elements in this viral genome are mhTERT promoter driving
a mutant E1A region (01/07). The expression cassette containing sTGFβRIIFc was
introduced in E3 region. Rest of the genome (E1B, E2B, L1-L5, and E4) is similar to wild
type Ad5.
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Fig. 3.
mhTERTAd.sTβRFc and Ad(E1-).sTβRFc -mediated expression of sTGFβRIIFc protein in
breast cancer cells. Breast cancer cells were infected with either mhTERTAd.sTβRFc,
Ad(E1-).sTβRFc or Ad(E1-).Null (100 pfu/cell) for 24 hrs. At the end of the incubation,
media were changed into serum free media, and the incubations continued for an additional
24 hrs. A. Western blot analysis of sTGFβRIIFc protein. Cells and media were subjected to
Western blot analysis for sTGFβRIIFc expression and are shown in the Figure. B. ELISA
assays of sTGFβRIIFc protein. Aliquots of media samples were analyzed for sTGFβRIIFc
by ELISA as described in materials and methods. Shown are the averages of triplicate
samples (±SE).
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Fig. 4.
A. The binding of TGβ-1 with sTGFβRIIFc. One μg of sTGFβRIIFc was mixed with 40 ng
of TGFβ-1 (Sigma, St. Louis, MO) for 1 hour at 4°C and then incubated with Protein-A
Sepharose beads (Vector Laboratories, Burlingame, CA) for 1 hour at 4°C. The bound
TGFβ-1 was released with acidic buffer as described in materials and methods. The samples
were subjected to Western blot analysis and probed with rabbit anti-TGFβ-1 polyclonal
antibody (R & D systems, Minneapolis, MN). Note TGFβ-1 band is present when TGFβ-1
was pre-incubated with sTGFβRIIFc (lane 1), but not without sTGFβRIIFc (Lane 2). Lane 3
received pure TGFβ-1 as a positive control for Western blot. B. Inhibition of TGFβ-
dependent SMAD-3 phosphorylation by sTGFβRIIFc. MDA-MB-231 cells were plated in 6-
well plates (4×105 cells/well). Next day, media was changed and cells were incubated with
TGFβ-1 (1 ng/ml) in the absence or presence of media containing sTGFβRIIFc or purified
sTGFβRIIFc (100 ng/ml) for 60 minutes. Cell lysates were prepared and further subjected to
Western blot analysis. Blots were probed with phospho SMAD3 antibody, or Smad2/3
antibody (Cell Signaling, Danvers, MA).
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Fig. 5.
A. mhTERTAd.sTβRFc titers in breast tumor and normal human cells. MDA-MB-231,
MCF-7 and IMR-90 cells were plated in 6-well dishes (2×105 cells/well). Cells were
infected with mhTERTAd.sTβRFc (100 pfu/cell) for either 3 hrs or 48 hrs as described in
Materials and Methods. Cell lysates and supernatants were collected and viral titers were
measured by plaque forming assays in HEK-293 cells. Results shown are average of three
determinations ± SE. B. Comparison of viral burst sizes. Shown are the increases in the viral
titers during 48 hrs infection (burst sizes) of the mhTERT.AdsTβRFc in MDA-MB-231,
MCF-7 and IMR-90 cells. The mhTERT.AdsTβRFc burst size in IMR-90 cells was
significantly lower compared to burst sizes in MDA-MB-231 or MCF-7 cells (p values <
0.001).
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Fig. 6.
A. In vivo evaluation of mhTERTAd.sTβRFc administration on MDA-MB-231 tumor
xenograft in nude mice. MDA-MB-231 cells were injected subcutaneously (5×106 cells per
mouse). Once tumor sizes reached about 50 mm3, mhTERTAd.sTβRFc (n=13)
Ad(E1-).sTβRFc (n= 12), Ad(E1-).Null (n=10) or buffer (n=11) were administered into the
tail vein. The virus dose was 2×108 pfus in 0.1 ml buffer per injection; two injections total
on days 0 and 3. Tumor volumes were measured using a digital caliper on various days
shown. The tumor volumes were calculated using the formula (a × b2) × 0.523. Results show
the tumor volumes in animals that received intravenous injections of mhTERTAd.sTβRFc
(▲), Ad(E1-).sTβRFc (■) Ad(E1-).Null (▼)or buffer (●). The tumor growth of various
groups were compared with buffer control groups using two-way Anova, and further
evaluated by Bonferroni post hoc test using Graph Pad Prism 5 software. Compared to
buffer group the p value for mhTERTAd.sTβRFc group is <0.01 (*), p value for
Ad(E1-).sTβRFc is >0.05, and p value for Ad(E1-).Null is >0.05. B. Blood levels of
sTGFβRIIFc in mhTERTAd.sTβRFc or Ad(E1-).sTβRFc treated animals. Blood was
collected on day 35 (Fig. 6A) and analyzed for the expression of sTGFβRIIFc by ELISA.
Shown are the sTGFβRIIFc levels in animals that received the buffer, Ad(E1-).Null,
Ad(E1-).sTβRFc or mhTERTAd.sTβRFc.
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